Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bari – page 11

401 clinical trials in Bari, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bari at a glance
401
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

401 trials in Bari

Open in trial search

Gastroenteropancreatic neuroendocrine tumour disease

Recruiting

Study on the Safety and Effectiveness of Cabozantinib and Lanreotide for Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Neoplasm+1

Recruiting

Study of NVL-655 for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with ALK Mutation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:NVL-655
  • Sponsor:Nuvalent Inc.

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Study on the Safety and Effectiveness of EIK1001 and Pembrolizumab for Patients with Advanced Melanoma

Recruiting
Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Systemic scleroderma+1

Recruiting

Study on the Effects of Belimumab in Adults with Systemic Sclerosis-Associated Interstitial Lung Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer metastatic

Recruiting

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Prostate cancer metastatic

Recruiting

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Recruiting

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Polycythaemia vera

Recruiting

Study Comparing Givinostat and Hydroxyurea for Patients with High-Risk Polycythemia Vera

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carbasalate Calcium
  • Sponsor:Italfarmaco S.p.A.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Bari

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for various cancers, including metastatic colorectal cancer, non-small cell lung cancer, and malignant pleural mesothelioma. Research evaluates new therapeutic approaches and drug combinations.

  • Colorectal Cancer Treatment Studies
  • Lung Cancer Therapies
  • Mesothelioma Management

Advanced clinical trials testing targeted therapies and immunotherapy approaches.

02 Infectious Disease Prevention

Investigations into vaccines and preventive treatments for various infectious conditions, particularly respiratory syncytial virus (RSV) and influenza. Studies include both pediatric and adult populations.

  • Vaccine Development
  • RSV Prevention
  • Influenza Protection

Focus on immunogenicity and safety in different age groups.

03 Hematologic Disorders

Research examining treatments for blood-related conditions, including chronic myeloid leukemia and acute myeloid leukemia. Studies evaluate novel therapeutic approaches and drug combinations.

  • Leukemia Treatments
  • Targeted Therapies
  • Clinical Outcomes

Emphasis on personalized treatment approaches and molecular targeting.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.